The Alliance for Regenerative Medicine (ARM) today released its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering, and broader global regenerative medicine sector trends and metrics in the first quarter of 2019.
By further curating information provided by ARM’s data partner Informa, the quarterly data report details industry-specific statistics compiled from 917 cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.
Amanda Micklus, a senior consultant for Pharma Intelligence at Informa, provided an overview of the commercial, clinical, and regulatory environment in the first quarter of 2019. The report also features commentary from ARM’s 2019 Cell and Gene Investor Day. Investors and therapeutic developers weighed in on key issues in the sector, including the investment landscape, challenges in manufacturing at scale, and the outlook for these therapies over the next five to 10 years.
Highlighted findings from the Q1 2019 data report include:
ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trials by phase, and significant clinical data events.
The report is available online here, with interactive data and downloadable graphics from the report available here. For more information, please visit www.alliancerm.org or contact Lyndsey Scull at firstname.lastname@example.org.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 330 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.